These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23345305)

  • 21. Learning from previous responses in phase I dose-escalation studies.
    Whitehead J; Zhou Y; Stallard N; Todd S; Whitehead A
    Br J Clin Pharmacol; 2001 Jul; 52(1):1-7. PubMed ID: 11453884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 23. Response to comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by G. Yin, R. Lin and N. Wages.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):23-6. PubMed ID: 25492617
    [No Abstract]   [Full Text] [Related]  

  • 24. Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar.
    Wages NA
    Stat Med; 2015 Jan; 34(1):18-22. PubMed ID: 25492616
    [No Abstract]   [Full Text] [Related]  

  • 25. Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, and S. Zohar.
    Yin G; Lin R
    Stat Med; 2015 Jan; 34(1):13-7. PubMed ID: 25492615
    [No Abstract]   [Full Text] [Related]  

  • 26. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial improvement: a question of patient selection, trial design, or both?
    Ballman KV
    J Clin Oncol; 2014 Feb; 32(6):489-90. PubMed ID: 24419111
    [No Abstract]   [Full Text] [Related]  

  • 28. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
    Faries D
    J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial designs for targeted agents.
    Ma BB; Britten CD; Siu LL
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1287-305. PubMed ID: 12512393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
    Heath EI; LoRusso PM; Ivy SP; Rubinstein L; Christian MC; Heilbrun LK
    J Biopharm Stat; 2009; 19(3):414-23. PubMed ID: 19384685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adaptive dose-finding studies: a review of model-guided phase I clinical trials.
    Iasonos A; O'Quigley J
    J Clin Oncol; 2014 Aug; 32(23):2505-11. PubMed ID: 24982451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eligibility of patients with renal impairment for Phase I trials: Time for a rethink?
    Malik L; Mejia A; Weitman S
    Eur J Cancer; 2014 Nov; 50(17):2893-6. PubMed ID: 25241228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential designs for individualized dosing in phase I cancer clinical trials.
    Mao X; Cheung YK
    Contemp Clin Trials; 2017 Dec; 63():51-58. PubMed ID: 27592121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reply to D.M. Hyman et al and M. Voskoboynik et al.
    Ballman KV
    J Clin Oncol; 2014 Oct; 32(28):3200. PubMed ID: 25071106
    [No Abstract]   [Full Text] [Related]  

  • 38. Improving patient selection for phase I oncology trials.
    Voskoboynik M; Arkenau HT
    J Clin Oncol; 2014 Oct; 32(28):3198-9. PubMed ID: 25071142
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase 1 clinical trials: not just for safety anymore?
    Khandekar J; Khandekar M
    Arch Intern Med; 2006 Jul; 166(14):1440-1. PubMed ID: 16864752
    [No Abstract]   [Full Text] [Related]  

  • 40. Early phase cancer clinical trials: design, ethics and future directions.
    Coupe N; Gupta A; Lord SR
    Br J Hosp Med (Lond); 2015 Jul; 76(7):409-13. PubMed ID: 26140560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.